NeuroScientific Biopharmaceuticals (ASX:NSB) has appointed Robert McKenzie as Non-Executive Chairman, effective Friday, June 27, following the completion of its acquisition of Isopogen WA, holder of StemSmart, a patented stem cell technology, according to a same-day filing with the Australian bourse.
McKenzie succeeds outgoing Non-Executive Chairman Christopher Ntoumenopoulos and will receive 5 million unquoted options.
exercisable at AU$0.07 each and expiring three years from the date of issue, the filing said.
The company also appointed Marian Sturm as Chief Scientific Officer.
Shares of the company rose 4% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。